Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13218MR)

This product GTTS-WQ13218MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF9 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001561.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3604
UniProt ID Q07011
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13218MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7430MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ10783MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ1191MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ9036MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ4159MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI-754091
GTTS-WQ12571MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NV-02
GTTS-WQ13254MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ11280MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI4893
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW